Dimitrios Farmakiotis

[David Leaf @DavidLeaf9]

Excited to share our study on RBC exchange transfusion in severe babesiosis, now in @JAMAInternalMed. With Peter Krause and collaborators across 82 hospitals, we found substantially improved clinical outcomes in severe disease.
https://t.co/s4XAcb4e2v

[Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 @ABsteward]

🆕️🔥The largest real-world, multicenter study of dalbavancin use for Gram-positive BSI @NicholasRebold @IDpharmresearch and many @SIDPharm 🌟s
Dalbavancin Sequential Therapy for Gram-Positive Bloodstream Infection #IDXposts #DOTS
https://t.co/FOh8iUXInq

[Dimitrios Farmakiotis @DFarmakiotis]

Second published case (tok) of TOA abscess caused by #Ureaplasma, first (tok) diagnosed by #Karius_test, #cfDNA in plasma. ⁦@noufkmag⁩ ⁦@BrownIDprogram⁩ @KariusInc⁩ ⁦@sharmaphrm⁩ https://t.co/et5pK2HQhk

[Dimitrios Farmakiotis @DFarmakiotis]

Promising results from our investigator-initiated prospective study of a commercially available CMV T-cell immunity assay! @noufkmag⁩, ⁦@BrownIDprogram⁩, ⁦@eurofinsviracor⁩ https://t.co/RODlDbGcGX

[Anna Apostolopoulou, MD @AnnaApostolopo3]

Time to challenge the dogma of steroids for severe PJP? Our multicenter retrospective study of PJP in SOTRs led by Drs Hosseini-Moghaddam and Fishman did not find an association between steroids and mortality in SOTRs https://t.co/fvR0iS0yu3 @amjtransplant #IDTwitter

[Eurofins Viracor @eurofinsviracor]

📣 Webinar ALERT! Thursday, Nov. 16th. 1pm EST

Register NOW for ‘A Paradigm of Precision Medicine: Clinical utilization of CMV inSIGHT™ T Cell Immunity Testing,’ presented by Dr. Dimitrios Farmakiotis.

💻 11/16 | 1:00pm EST
🦠 REGISTER 👇

🗣 @DFarmakiotis #IDtwitter #CMV

[Nouf Almaghlouth @noufkmag]

I was honored to present our research work under the lead of Dr. Farmakiotis @DFarmakiotis on the utility of CMV-specific T-cell mediated immunity panel (TCIP) to predict protection against CMV among kidney transplant recipients #IDWeek2023 #IDWeekmtg #WeAreID #TxID

[Nouf Almaghlouth @noufkmag]

Thrilled to represent our @BrownIDprogram at the @IDWeekmtg Special thanks to Dr @DFarmakiotis for his research mentorship & thorough guidance.

Grateful to our PD, Dr. Cunha, Dr @MarthaCSanchezD for their immense support & motivation #IDWeek2023 #WeAreID #TxID

[Michael Ison, MD MS @MichaelGIsonMD]

It was a huge honor to work on this important study - the RSV vaccine adds to our armamentarium to keep our older adults safe from the scourge of this important pathogen. Thanks to the dedicated @NM_Transplant research team for their support.

https://t.co/jD9RGBMixm

[Wafik S. El-Deiry, MD, PhD, FACP @weldeiry]

Learning @BrownMedicine @BrownPhysicians medicine grand rounds on post-transplant lymphoproliferative disease, fatal pulmonary mucormycosis diagnosed by PCR, Karius liquid biopsy @OllilaTom comments while biking, @drabbaseabbas @DFarmakiotis Dimitrios Kontoyiannis @MDAndersonNews

[Toni Choueiri, MD @DrChoueiri]

Using @COVID19nCCC dataset, we show that Vaccination against COVID-19, especially with additional doses, is a fundamental strategy in the prevention of adverse outcomes including death, among patients with Cancer!

Congrats #CCC19 team!

Our paper in @LancetRH_Americ

@DanaFarber @BrownUniversity @VUMChealth @harvardmed @US_FDA

https://t.co/MkNgLCNvC1

[Dimitrios Farmakiotis @DFarmakiotis]

mRNA vaccination decreases COVID-19-associated morbidity and mortality among organ transplant recipients: a contemporary cohort study | Open Forum Infectious Diseases | Oxford Academic Vaccines work led by ⁦@BrownMedicine⁩ MS ⁦@BrownIDprogram⁩ https://t.co/WJEhcNeFL7

[Open Forum Infectious Diseases @OFIDJournal]

mRNA vaccination decreases COVID-19-associated morbidity and mortality among organ transplant recipients: a contemporary cohort study

✅ Just Accepted
🔓 Open Access
🔗 https://t.co/K9r2PhKBbs

[COVID-19 and Cancer Consortium (CCC19) Registry @COVID19nCCC]

The COVID-19 and Cancer Consortium (CCC19) Publications: https://t.co/o88D5f10VX [7/15/22] #COVID19nCancer @COVID19nCCC #CCC19 #COVID19 @Ecquis @hemoncwarner Partial List...

[Toni Choueiri, MD @DrChoueiri]

Trying to write a grant during weekdays…

https://t.co/aXjAlRr5Ct

[Dimitrios Farmakiotis @DFarmakiotis]

IDSA COVID-19 OUTPATIENT TREATMENT GUIDELINES ROADMAP: High titer conv plasma for outpatient management of COVID-19 in the immunosuppressed ⁦@COVID19nCCC⁩ ⁦@mtmdphd⁩ https://t.co/2Zl7ZmxDOw

[COVID-19 and Cancer Consortium (CCC19) Registry @COVID19nCCC]

Map of Participating Institutions (N=126) - COVID-19 and Cancer Consortium (#CCC19) [Apr 20, 2022] https://t.co/xqZPC8wTjd #NCT04354701 #COVID19nCancer #COVID19 @COVID19nCCC

[Dimitrios Farmakiotis @DFarmakiotis]

Deskins Candies Recalls Peanut Butter Fudge, Peanut Butter No Bake, Chocolate No Bake, and Peanut Butter Pinwheel Because of Possible Health Risk https://t.co/J2F3sInNUl‘MVpeanut-butter-fudge-peanut-butter-no-bake-chocolate-no-bake-and-peanut

[Dimitrios Farmakiotis @DFarmakiotis]

Single‐center experience with nirmatrelvir/ritonavir in kidney transplant recipients on tacrolimus maintenance immunosuppression https://t.co/ojsVluH6h5 Important work on #Paxlovid drug drug interactions, again with @BrownMedicine #trainee contribution. @BrownIDprogram

[Chris Labaki @Chrislabaki1]

1/ Happy to share with you our work on oncology clinical trial disruption during the pandemic out @Annals_Oncology @myESMO , with co-1st @ZiadBakouny @SheenaBhallaMD @dr_aschmidt and the amazing guidance of @DDoroshow @DrChoueiri @MattGalsky

Link: https://t.co/dleNsLynza